Full history for every metric is available with a Kvantra account
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €bn | 14.5 | 18.0 | 21.7 | 21.7 | 22.4 | 23.4 | 23.2 | 23.6 |
| Operating profit | €bn | 3.44 | 3.44 | ||||||
| Net profit | €bn | 1.41 | 1.73 | 2.04 | 1.51 | 1.94 | 2.14 | 2.21 | 2.64 |
| EPS reported | € | 1.91 | 1.98 | ||||||
| Operating cashflow per share | € | 2.75 | 2.71 | ||||||
| Capex per share | € | 0.73 | 0.73 | ||||||
| FCF per share | € | 2.02 | 1.98 | ||||||
| Free cash flow | €bn | 2.27 | 2.22 | ||||||
| Net debt | €bn | 12.4 | 12.6 | ||||||
| Book value equity | €bn | 18.0 | 19.1 | ||||||
| Book value per share | € | 16.04 | 17.07 | ||||||
| Number of shares | m | 1,124.74 | 1,119.2 | ||||||
| DPS (TTM paid) | € | 1.00 | 1.00 |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 24.09 | 20.16 | ||||||
| P/B LTM | x | 2.86 | 2.22 | ||||||
| P/S LTM | x | 2.20 | 1.83 | ||||||
| P/FCF LTM | x | 22.75 | 19.13 | ||||||
| EV/EBITDA LTM | x | 14.05 | 12.16 | ||||||
| EV/Sales LTM | x | 2.76 | 2.37 | ||||||
| Earnings Yield LTM | % | 4.15% | 4.96% | ||||||
| FCF Yield | % | 4.40% | 5.23% | ||||||
| Quality | |||||||||
| ROE | % | 11.88% | 12.00% | ||||||
| ROIC | % | 7.36% | 7.32% | ||||||
| Operating margin | % | 14.70% | 14.84% | ||||||
| Gross margin | % | 38.63% | 39.02% | ||||||
| FCF/Sales | % | 9.69% | 9.56% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +10.40% | +2.59% | ||||||
| Sales Growth YoY | % | +4.53% | -0.92% | ||||||
| Net Income Growth YoY | % | +10.40% | +1.89% | ||||||
| FCF Growth | % | +27.75% | -15.52% | ||||||
| Operating Profit Growth | % | +4.09% | -8.90% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 2.07% | 2.51% | ||||||
| Dividend Growth | % | +5.26% | +5.26% | ||||||
| Payout Ratio | % | 49.62% | 50.38% | ||||||
| FCF/Debt | x | 0.15 | 0.15 | ||||||
| Net Debt/EBITDA | x | 2.81 | 2.79 | ||||||
| EBIT/Net interest | x | 8.08 | 8.45 | ||||||
| Net debt/market cap | % | 24.03% | 29.84% | ||||||
| Net debt/Equity | x | 0.69 | 0.66 | ||||||
| Gross debt/equity | x | 0.83 | 0.79 | ||||||
ETFs that hold Siemens Healthineers
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| iShares TecDAX UCITS ETF (DE) | EXS2.DE | 4 | 11.04% |
| Amundi TecDAX UCITS ETF Dist | E908.DE | 4 | 10.89% |
| VanEck Morningstar International Moat ETF | MOTI | 5 | 2.62% |
Funds with Siemens Healthineers among their ten largest holdings, largest fund first.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Siemens Healthineers AG, a subsidiary of Siemens Aktiengesellschaft with its headquarters in Erlangen, Germany, is a global leader in medical technology. The company develops, produces, and distributes a comprehensive portfolio of diagnostic and therapeutic products and services, catering to healthcare providers worldwide. Its operations are organized into four distinct business segments. The Imaging segment delivers advanced medical imaging systems, encompassing magnetic resonance imaging (MRI), computed tomography (CT), X-ray technology, molecular imaging, and ultrasound solutions. The Diagnostics segment focuses on providing in-vitro diagnostic products and services for laboratory, molecular, and point-of-care applications, alongside workflow optimization tools and informatics solutions for healthcare facilities. Varian, another key segment, specializes in cancer care, offering cutting-edge technologies, services, and integrated solutions to hospital oncology departments. This includes enhancing workflow efficiency, providing clinical services and consulting, and deploying digital platforms for treatment and therapy management. Lastly, the Advanced Therapies segment supplies sophisticated products designed to facilitate image-guided minimally invasive treatments across various medical fields, such as cardiology, interventional radiology, and surgery. Its offerings include angiography systems, mobile C-arms, and a robotic-assisted platform specifically for endovascular coronary and peripheral vascular procedures. Beyond these core offerings, Siemens Healthineers also provides a suite of essential support services, such as equipment performance management, clinical education and e-learning programs, asset management, managed departmental services for laboratories and healthcare facilities, and expert consulting and digital health services.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Siemens Healthineers AG (SHL.DE)
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| iShares TecDAX UCITS ETF (DE) | EXS2.DE | 4 | 11.04% |
| Amundi TecDAX UCITS ETF Dist | E908.DE | 4 | 10.89% |
| VanEck Morningstar International Moat ETF | MOTI | 5 | 2.62% |
Funds with Siemens Healthineers among their ten largest holdings, largest fund first.
Based on consensus from external analysts. Not Kvantra's opinion.
Siemens Healthineers AG, a subsidiary of Siemens Aktiengesellschaft with its headquarters in Erlangen, Germany, is a global leader in medical technology. The company develops, produces, and distributes a comprehensive portfolio of diagnostic and therapeutic products and services, catering to healthcare providers worldwide. Its operations are organized into four distinct business segments. The Imaging segment delivers advanced medical imaging systems, encompassing magnetic resonance imaging (MRI), computed tomography (CT), X-ray technology, molecular imaging, and ultrasound solutions. The Diagnostics segment focuses on providing in-vitro diagnostic products and services for laboratory, molecular, and point-of-care applications, alongside workflow optimization tools and informatics solutions for healthcare facilities. Varian, another key segment, specializes in cancer care, offering cutting-edge technologies, services, and integrated solutions to hospital oncology departments. This includes enhancing workflow efficiency, providing clinical services and consulting, and deploying digital platforms for treatment and therapy management. Lastly, the Advanced Therapies segment supplies sophisticated products designed to facilitate image-guided minimally invasive treatments across various medical fields, such as cardiology, interventional radiology, and surgery. Its offerings include angiography systems, mobile C-arms, and a robotic-assisted platform specifically for endovascular coronary and peripheral vascular procedures. Beyond these core offerings, Siemens Healthineers also provides a suite of essential support services, such as equipment performance management, clinical education and e-learning programs, asset management, managed departmental services for laboratories and healthcare facilities, and expert consulting and digital health services.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free